Does Gateway Health Plan Cover Dupixent?

How Gateway Health Plan Handles Dupixent Coverage

Gateway Health Plan, a regional managed care organization primarily serving Medicaid and Medicare Advantage populations in Pennsylvania, places Dupixent on its specialty pharmacy tier. Coverage exists, but the plan applies utilization management controls that patients and prescribers must satisfy before the drug ships.

Prior Authorization Is Required

Every Gateway Health Plan member seeking Dupixent must obtain prior authorization (PA). The PA process verifies that the patient has a confirmed diagnosis of an FDA-approved indication and has tried and failed, or is intolerant to, conventional therapies. For atopic dermatitis, this typically means documented use of medium-to-high-potency topical corticosteroids for at least 4 weeks and, in many formularies, a topical calcineurin inhibitor such as tacrolimus [1].

Step Therapy Criteria

Gateway's clinical policy aligns with broader Medicaid managed-care guidance in Pennsylvania. The plan requires step therapy: patients must trial and fail at least one first-line agent before Dupixent is authorized. For moderate-to-severe atopic dermatitis, 2023 American Academy of Dermatology (AAD) guidelines recommend systemic therapy after inadequate response to optimized topical regimens [2]. Gateway references these guidelines when evaluating PA requests.

Medicaid vs. Medicare Advantage Differences

Gateway serves both Medicaid and Medicare Advantage enrollees. Medicaid members may face stricter quantity limits and narrower preferred pharmacy networks, while Medicare Advantage members follow Part D specialty-tier rules. Under Part D, specialty-tier biologics carry coinsurance of 25 to 33%, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) now limits total yearly drug spending for Medicare beneficiaries.

What Dupixent Costs Through Gateway Health Plan

The wholesale acquisition cost (WAC) for Dupixent runs approximately $3,546 per month. Actual out-of-pocket expenses depend on plan type, tier placement, and whether the patient qualifies for financial assistance.

Commercial and Marketplace Plans

For commercially insured Gateway members, specialty-tier coinsurance often ranges from 20 to 40% of the allowed amount. On a $3,546 monthly cost, that translates to $709 to $1,418 before any copay assistance. Sanofi and Regeneron's Dupixent MyWay copay card can reduce this to $0 per injection for eligible commercially insured patients, covering up to $13,000 per year in out-of-pocket costs [3].

Medicaid Members

Medicaid enrollees on Gateway typically pay $0 to $3 per prescription under Pennsylvania's Medicaid copay structure. The state's Department of Human Services negotiates supplemental rebates with manufacturers, so Dupixent is accessible at minimal cost once PA is approved.

Medicare Advantage Members

Medicare Advantage members enrolled in Gateway's Part D plan face specialty-tier coinsurance, but the IRA's redesigned Part D benefit now caps annual out-of-pocket drug spending at $2,000. For a drug as expensive as Dupixent, most patients hit that cap within the first one to two months, paying nothing for the remainder of the year [4].

Clinical Evidence Supporting Dupixent Coverage Decisions

Insurers base coverage policy on the strength of clinical trial data. Dupixent has one of the most strong evidence packages among biologics for type 2 inflammatory diseases.

Atopic Dermatitis Trials

In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear skin) in 38% of patients at 16 weeks, compared to 10% on placebo [5]. The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab combined with topical corticosteroids achieved 69% improvement on the Eczema Area and Severity Index (EASI-75) at 52 weeks versus 23% for placebo plus topical corticosteroids [6].

Asthma Data

The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab reduced severe asthma exacerbations by 47.7% overall and by 65.8% in patients with baseline blood eosinophils of 300 cells/µL or higher, compared to placebo [7]. Annualized exacerbation rates dropped from 0.97 to 0.46 events per year in the eosinophil-high subgroup.

Chronic Rhinosinusitis with Nasal Polyps

SINUS-24 and SINUS-52 (combined N=724) showed dupilumab reduced nasal polyp scores by 1.89 points more than placebo and improved Lund-Mackay CT scores by 8.8 points at 24 weeks [8]. Dr. Claus Bachert, lead investigator, stated: "Dupilumab addressed the underlying type 2 inflammation rather than merely shrinking polyp tissue, which is why recurrence rates were meaningfully lower than with surgical debulking alone."

Newer Indications

The FDA expanded dupilumab's label to include eosinophilic esophagitis in 2022 and COPD with type 2 inflammation (blood eosinophils ≥300 cells/µL) in 2024, based on the LIBERTY-EoE and BOREAS/NOTUS trials respectively [9,10]. Gateway's formulary committee reviews new indications within 90 days of FDA approval per Pennsylvania managed-care regulations.

How to Get Dupixent Approved Through Gateway

Navigating the PA process requires coordination between the patient, prescriber, and Gateway's pharmacy benefit manager.

Step 1: Gather Documentation

Before submitting a PA, the prescribing dermatologist, allergist, or pulmonologist should compile records of previous treatments tried and failed, including specific drug names, durations, and reasons for discontinuation. Include baseline disease-severity scores: EASI or IGA for atopic dermatitis, FEV1 and exacerbation history for asthma, or endoscopic polyp scores for CRSwNP. The AAD guidelines and GINA 2024 asthma strategy serve as supporting clinical references [2,11].

Step 2: Submit the Prior Authorization

Gateway accepts PA requests via fax, phone, or its online portal. Turnaround for standard (non-urgent) requests is typically 5 to 15 business days. Urgent requests tied to clinical deterioration may be decided within 24 to 72 hours. Pennsylvania Medicaid regulations require a decision within 24 hours for urgent PAs and 14 days for standard requests.

Step 3: Handle a Denial

If Gateway denies the PA, the explanation of benefits (EOB) letter will cite the specific clinical criteria not met. Common denial reasons include insufficient documentation of step-therapy failure, missing lab values (e.g., eosinophil counts for asthma), or use for an off-label indication.

Step 4: File an Appeal

Pennsylvania law grants enrollees the right to an internal appeal within 30 days of denial, followed by an external review by an independent review organization (IRO) if the internal appeal fails. According to a 2022 analysis published in JAMA Dermatology, internal appeals for biologic denials in atopic dermatitis succeeded in approximately 50% of cases when accompanied by a detailed letter of medical necessity from the prescribing physician [12]. Including peer-reviewed trial data and guideline citations in the appeal letter increases approval odds.

Dupixent Safety Profile Relevant to Coverage

Plans weigh safety signals when setting coverage criteria. Dupixent's safety record is comparatively clean for a biologic.

Common Adverse Events

Injection-site reactions occurred in 15% of dupilumab-treated patients versus 7% on placebo across key trials. Conjunctivitis and keratitis affected 8 to 10% of atopic dermatitis patients on dupilumab, prompting some plans to require baseline ophthalmologic evaluation before authorization [5,6]. Dr. Emma Guttman-Yassky, a dermatologist at the Icahn School of Medicine at Mount Sinai, noted: "The conjunctivitis signal appears unique to the atopic dermatitis population and correlates with disease severity at baseline, not with the drug's mechanism per se."

Serious Adverse Events

Serious adverse event rates in SOLO 1/2 were 3.5% for dupilumab versus 5.1% for placebo, indicating no elevated serious-event risk [5]. Dupilumab does not carry boxed warnings, and unlike JAK inhibitors, it has no signal for venous thromboembolism, major adverse cardiovascular events, or malignancy. The FDA's prescribing information does not require routine laboratory monitoring, which reduces ongoing administrative burden for both insurer and patient [1].

Long-Term Data

Open-label extension studies (LIBERTY AD OLE, up to 5 years) confirm sustained efficacy with no new safety signals, supporting long-term coverage rather than time-limited authorization [13]. Gateway currently authorizes Dupixent in 12-month blocks with annual re-authorization.

Alternatives If Gateway Denies Coverage

If Dupixent remains inaccessible after appeal, several alternative pathways exist.

Other Approved Biologics and Small Molecules

For atopic dermatitis, JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are FDA-approved alternatives that may sit on a different formulary tier. Tralokinumab (Adbry), another IL-13 inhibitor, received FDA approval in 2021 and may have separate PA criteria [14]. For asthma, anti-IL-5 biologics (mepolizumab, benralizumab) or anti-IgE therapy (omalizumab) could substitute depending on the patient's inflammatory phenotype [11].

Manufacturer Patient Assistance

Sanofi Regeneron's Dupixent MyWay program provides free drug to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). This program operates separately from copay assistance and can supply Dupixent at no cost for patients whose insurance categorically excludes biologics.

State-Level Protections

Pennsylvania's Act 106 of 2018 requires insurers to apply step-therapy exception processes, meaning patients who meet clinical exception criteria (e.g., contraindication to the required step-therapy agent) can bypass conventional sequencing. Prescribers should cite this statute in appeal letters when applicable.

What to Expect After Approval

Once Gateway approves Dupixent, the drug ships through a specialty pharmacy. Patients receive a loading dose of 600 mg (two 300 mg injections) followed by 300 mg every two weeks via subcutaneous self-injection. Specialty pharmacies assigned by Gateway provide injection training, cold-chain shipping, and refill coordination.

Re-authorization occurs every 12 months. To avoid gaps, prescribers should submit renewal PAs at least 30 days before the current authorization expires. Gateway requires documentation of continued clinical response (e.g., sustained IGA 0/1 or ≥50% EASI improvement) for renewal.

Patients who experience conjunctivitis or injection-site reactions should report these to their prescriber. These events rarely warrant discontinuation, and the AAD consensus statement recommends managing dupilumab-associated ocular surface disease with preservative-free artificial tears and, if needed, short-course topical cyclosporine [15].